Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD

Published: Thursday, Nov 09, 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

SEE ALL VIDEOS FROM: Jonathan Brammer, MD

View more on OncLive TV >>>

Trending Now

FDA Approves Talazoparib for BRCA-Mutated, HER2-Negative Breast Cancer

CD22 Emerges as CAR T-Cell Therapy Target

FDA Grants Olaparib Orphan Drug Designation for Pancreatic Cancer

Step Therapy Policy Alarms Cancer Leaders

Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial

Novel Combination Shows Early Efficacy in Ovarian Cancer

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

Brentuximab Vedotin Approved in Europe for CTCL

Expert Highlights Advances in Cutaneous T-Cell Lymphoma

Related Videos

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

View Conference Coverage

2018 State of the Science Summit on Hematologic Malignancies in Clayton

State of the Science Summit on GI Cancers in Newport Beach

2018 ESMO Congress

2018 State of the Science Summit on Hematologic Malignancies in Cleveland

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®	Oct 31, 2018	1.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and Vomiting	Oct 31, 2018	2.0